Want to join the conversation?
Tim Anderson of Sanford Bernstein asks for an update on Jardiance. $LLY said a new label with an indication for reduction of cardiovascular death will be significant. The company has good coverage and access. $LLY is at 85% plus in commercial and above 70% in Part D and the access will get stronger when it gets the label.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.